The Role of MSC in the Treatment of Fistulas in Patients With Perianal Crohn's Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03056664 |
Recruitment Status : Unknown
Verified September 2016 by Sixth Affiliated Hospital, Sun Yat-sen University.
Recruitment status was: Not yet recruiting
First Posted : February 17, 2017
Last Update Posted : February 17, 2017
|
Sponsor:
Sixth Affiliated Hospital, Sun Yat-sen University
Information provided by (Responsible Party):
Sixth Affiliated Hospital, Sun Yat-sen University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Here investigators will carry out this phase II clinical trial to explore a effective therapeutic regimen of MSC in the Crohn's perianal fistula.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Crohn's Disease Fistula | Procedure: Routine drainage surgery Biological: MSC injection 01 Biological: MSC injection 02 Other: placebo | Phase 2 Phase 3 |
Peri-anal fistula is common seen in Crohn's disease. Treatments including surgery, antibiotics, immunosuppressive drug and infliximab improve the quality of life of the patients suffering Crohn's perianal fistula, but the recurrent rate is still high. MSC showed promising effect in the therapy of CD, but the standard treatment strategy is unclear. Here investigators will carry out this phase II clinical trial to explore a effective therapeutic regimen of MSC in the Crohn's perianal fistula.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 3 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The Safety and Efficiacy of Local MSC Injection in the Treatment of Fistulas in Patients With Perianal Crohn's Disease |
Study Start Date : | January 2017 |
Estimated Primary Completion Date : | December 2019 |
Estimated Study Completion Date : | December 2019 |
Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics:
Crohn disease
Arm | Intervention/treatment |
---|---|
Experimental: MSC-1
Patient in this arm will receive routine surgery and local MSC injection of 3×10E6/kg
|
Procedure: Routine drainage surgery Biological: MSC injection 01 Local MSC injection in peri-anal with a dose of 3×10E6/kg |
Experimental: MSC-2
Patient in this arm will receive routine surgery and local MSC injection of 6×10E6/kg
|
Procedure: Routine drainage surgery Biological: MSC injection 02 Local MSC injection in peri-anal with a dose of 6×10E6/kg |
Experimental: Ctrl
Patient in this arm will receive routine surgery and local NS injection
|
Procedure: Routine drainage surgery Other: placebo NS injection instead of MSC |
Primary Outcome Measures :
- Clinical response(fistula closure) [ Time Frame: 12 weeks ]Physical examination indicates fistula healing, or MRI examinations showed fistula healing more than 2cm
Secondary Outcome Measures :
- C-reactive protein (CRP) [ Time Frame: 12 weeks ]To summarize the changes from baseline compared to 12 weeks in serum C-reactive protein (CRP)
- Clinical Response [ Time Frame: 6 weeks after receiving treatment ]CDAI means Crohn's Disease Activity Index.The purpose of this crohn's disease activity index (CDAI) calculator is to gauge the progress or lack of progress for people with crohn's disease. The reference article says "generally speaking, CDAI scores below 150 indicate a better prognosis than higher scores." Clinical Response of patients 6 weeks after receiving treatment (CDAI score less than 150)
Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age 18-65 years old, male or female;
- refractory CD fistula, there are 1-2 and 1-3 in the mouth fistula;
- Diagnostic CD at least three months;
- CDAI <250;
- were receiving drug treatment (5-ASA and hormones> 4 weeks, immunosuppressants and biological agents> 8 weeks);
- signed informed consent.
Exclusion Criteria:
- with intestinal obstruction, stenosis, or perianal abscess;
- pregnant or lactating women;
- infection needs antibiotics persons;
- rectovaginal fistula;
- complex anal fistula more than two inside the mouth;
- stenosis or perforation CD;
- perianal infection;
- could not do rectal or anal stenosis local injection therapy;
- with acute enteritis;
- , liver and kidney dysfunction;
- a month have used other drugs are in clinical trials;
- no conditions or unwilling to carry out MRI inspected;
- who are adjusting therapy;
- HIV patients;
- The combined active hepatitis or tuberculosis; Occurred in 16) 6 months opportunistic infections, or severe infections occur within three months;
17) In the past five years, those who suffer from cancer; 18) there is a history of lymphoproliferative disease.
No Contacts or Locations Provided
Responsible Party: | Sixth Affiliated Hospital, Sun Yat-sen University |
ClinicalTrials.gov Identifier: | NCT03056664 |
Other Study ID Numbers: |
MSCINCDGL |
First Posted: | February 17, 2017 Key Record Dates |
Last Update Posted: | February 17, 2017 |
Last Verified: | September 2016 |
Additional relevant MeSH terms:
Crohn Disease Fistula Inflammatory Bowel Diseases Gastroenteritis |
Gastrointestinal Diseases Digestive System Diseases Intestinal Diseases Pathological Conditions, Anatomical |